SCHEMBL3138036

SCHEMBL3138036

CCC(C(N)=O)c1ccccc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.44
EPHX1 P07099 1/20 0.40
CYP2C19 P33261 2/20 0.38
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.36
NOS3 P29474 2/20 0.36
NOS1 P29475 2/20 0.36
NOS2 P35228 2/20 0.36
LMNA P02545 1/20 0.36
HSD17B10 Q99714 1/20 0.36
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP3A4 P08684 1/20 0.34
ALOX15 P16050 1/20 0.34
CYP26A1 O43174 1/20 0.34
HDAC3 O15379 2/20 0.33
HDAC4 P56524 2/20 0.33
HDAC1 Q13547 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL262673 0.84 HTT (0.45) HTTCYP2C19CYP2C9TSHRLMNA
SCHEMBL5504222 0.80 EPHX1 (0.41) EPHX1TSHRLMNAHSD17B10TRPM8
SCHEMBL2030601 0.80 ALDH1A1 (0.44) EPHX1TSHRLMNAHSD17B10ALDH1A1
SCHEMBL10515048 0.80 TSHR (0.55) HTTEPHX1TSHRLMNAHSD17B10
SCHEMBL11078508 0.79 HTT (0.39) HTTEPHX1CYP2C19CYP2C9IDO1
SCHEMBL9157016 0.79 PIN1 (0.46) HTTCYP2C19CYP2C9TSHR
SCHEMBL2032138 0.79 KCNQ2 (0.48) EPHX1ALDH1A1
SCHEMBL3364493 0.79 KCNQ2 (0.48) EPHX1LMNAALDH1A1CYP3A4
SCHEMBL15502391 0.79 EPHX1 (0.40) HTTEPHX1TSHRLMNAHSD17B10
SCHEMBL20567135 0.78 CA1 (0.43) HTTEPHX1CYP2C9TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9920010-B2 CXCR7 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2018-03-20 US disclosed
EP-3004082-B1 CXCR7 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2017-08-02 EP disclosed
US-20160107997-A1 CXCR7 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2016-04-21 US disclosed
EP-3004082-A1 CXCR7 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2016-04-13 EP disclosed
CN-103242214-B A kind of indole derivatives and preparation method thereof SHAANXI BUCHANG HIGH-TECH PHARMACEUTICAL CO., LTD. (CN) 2016-04-06 CN disclosed
CN-105263924-A Cxcr7 receptor modulators ACTELION PHARMACEUTICALS LTD 2016-01-20 CN disclosed
CN-103242230-B Quinolinone derivative and preparation method thereof SHAANXI BUCHANG HI TECH PHARMACEUTICAL CO LTD 2015-02-18 CN disclosed
WO-2014191929-A1 CXCR7 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2014-12-04 WO disclosed
US-20100216791-A1 PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS ASTRAZENECA (SE) 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160107997-A1 CXCR7 RECEPTOR MODULATORS CXCR1, CXCR5, CXCR2 HTT 3293/4885EPHX1 1893/4885CYP2C19 1049/4885
US-20100216791-A1 PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS BRAF, RAF1, ARAF HTT 4823/4885EPHX1 1768/4885CYP2C19 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.